The in vitro antileukemic activity of CBX was reinforced by in vivo experiments showing that CBX improves survival and limits the leukemic infiltration of the liver and spleen of mice developing an aggressive human AML. This evidence concerns the gene CBX1 and acute myeloid leukemia.